OncoMatch/Clinical Trials/NCT04440267
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Is NCT04440267 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for acute leukemia of ambiguous lineage.
Treatment: vincristine · daunorubicin · cyclophosphamide · L-Asparaginase · prednisone · mercaptopurine · methotrexate · dexamethasone · Tyrosine kinase inhibitor — In this prospective, single arm, open label, clinical trial, a total of 50 acute leukemia of ambiguous lineage patients will be enrolled. Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) after CR . Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors. The purpose of current study is to evaluate the clinical efficacy of ALL-based chemotherapy，effect of genetic abnormality and minimal residual disease (MRD) on prognosis in patients with acute leukemia of ambiguous lineage.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 2–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
Creatinine ≤ 1.5 x ULN
Liver function
Total bilirubin ≤ 1.5 x ULN; SGOT and SGPT ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related
Cardiac function
ejection fraction ≥ 45% on MUGA scan
Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x ULN; SGOT and SGPT ≤ 2.5 x ULN; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; Patients must have adequate cardiac function (ejection fraction ≥ 45 % on Multiple Gated Acquisition (MUGA) scan).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify